The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin

Eiichi Ogawa, Norihiro Furusyo, Kazuhiro Toyoda, Hiroaki Takeoka, Shinji Maeda, Jun Hayashi

Research output: Contribution to journalArticle

97 Citations (Scopus)

Abstract

The aim of this study was to assess the association between liver stiffness measured by transient elastography (FibroScan®) and the efficacy of pegylated interferon alpha-2b plus ribavirin combination treatment for patients with chronic hepatitis C virus (HCV) infection. We prospectively studied 145 Japanese patients with chronic HCV infection. FibroScan was done at baseline, at the end of treatment, and at 48 and 96 weeks after the end of treatment. The FibroScan values were significantly decreased for sustained virological response (SVR) patients (the mean rate of change; -16.2%, -32.2% and -43.5%) in comparison with non-SVR patients (-7.2%, -2.1% and +17.3%) at the end of treatment (P = 0.0127), and 48 weeks (P < 0.0001) and 96 weeks (P < 0.0001) after the end of treatment. Among the non-SVR patients, the FibroScan values were significantly decreased for patients with biochemical response (BR) (-17.9%, -30.0% and -27.1%) in comparison with non-BR (-4.1%, +6.4% and +30.6%) at the end of treatment (P = 0.0270), and 48 weeks (P < 0.0001) and 96 weeks (P < 0.0001) after the end of treatment. The FibroScan values may predict a progressively better clinical outcome for patients with successful virological and biochemical responses.

Original languageEnglish
Pages (from-to)127-134
Number of pages8
JournalAntiviral Research
Volume83
Issue number2
DOIs
Publication statusPublished - Aug 1 2009

Fingerprint

Elasticity Imaging Techniques
Ribavirin
Chronic Hepatitis C
Virus Diseases
Hepacivirus
Therapeutics
peginterferon alfa-2b
Liver

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Virology

Cite this

The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin. / Ogawa, Eiichi; Furusyo, Norihiro; Toyoda, Kazuhiro; Takeoka, Hiroaki; Maeda, Shinji; Hayashi, Jun.

In: Antiviral Research, Vol. 83, No. 2, 01.08.2009, p. 127-134.

Research output: Contribution to journalArticle

@article{f29d9f5cb23d40b5a25ed7345a936c31,
title = "The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin",
abstract = "The aim of this study was to assess the association between liver stiffness measured by transient elastography (FibroScan{\circledR}) and the efficacy of pegylated interferon alpha-2b plus ribavirin combination treatment for patients with chronic hepatitis C virus (HCV) infection. We prospectively studied 145 Japanese patients with chronic HCV infection. FibroScan was done at baseline, at the end of treatment, and at 48 and 96 weeks after the end of treatment. The FibroScan values were significantly decreased for sustained virological response (SVR) patients (the mean rate of change; -16.2{\%}, -32.2{\%} and -43.5{\%}) in comparison with non-SVR patients (-7.2{\%}, -2.1{\%} and +17.3{\%}) at the end of treatment (P = 0.0127), and 48 weeks (P < 0.0001) and 96 weeks (P < 0.0001) after the end of treatment. Among the non-SVR patients, the FibroScan values were significantly decreased for patients with biochemical response (BR) (-17.9{\%}, -30.0{\%} and -27.1{\%}) in comparison with non-BR (-4.1{\%}, +6.4{\%} and +30.6{\%}) at the end of treatment (P = 0.0270), and 48 weeks (P < 0.0001) and 96 weeks (P < 0.0001) after the end of treatment. The FibroScan values may predict a progressively better clinical outcome for patients with successful virological and biochemical responses.",
author = "Eiichi Ogawa and Norihiro Furusyo and Kazuhiro Toyoda and Hiroaki Takeoka and Shinji Maeda and Jun Hayashi",
year = "2009",
month = "8",
day = "1",
doi = "10.1016/j.antiviral.2009.04.002",
language = "English",
volume = "83",
pages = "127--134",
journal = "Antiviral Research",
issn = "0166-3542",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin

AU - Ogawa, Eiichi

AU - Furusyo, Norihiro

AU - Toyoda, Kazuhiro

AU - Takeoka, Hiroaki

AU - Maeda, Shinji

AU - Hayashi, Jun

PY - 2009/8/1

Y1 - 2009/8/1

N2 - The aim of this study was to assess the association between liver stiffness measured by transient elastography (FibroScan®) and the efficacy of pegylated interferon alpha-2b plus ribavirin combination treatment for patients with chronic hepatitis C virus (HCV) infection. We prospectively studied 145 Japanese patients with chronic HCV infection. FibroScan was done at baseline, at the end of treatment, and at 48 and 96 weeks after the end of treatment. The FibroScan values were significantly decreased for sustained virological response (SVR) patients (the mean rate of change; -16.2%, -32.2% and -43.5%) in comparison with non-SVR patients (-7.2%, -2.1% and +17.3%) at the end of treatment (P = 0.0127), and 48 weeks (P < 0.0001) and 96 weeks (P < 0.0001) after the end of treatment. Among the non-SVR patients, the FibroScan values were significantly decreased for patients with biochemical response (BR) (-17.9%, -30.0% and -27.1%) in comparison with non-BR (-4.1%, +6.4% and +30.6%) at the end of treatment (P = 0.0270), and 48 weeks (P < 0.0001) and 96 weeks (P < 0.0001) after the end of treatment. The FibroScan values may predict a progressively better clinical outcome for patients with successful virological and biochemical responses.

AB - The aim of this study was to assess the association between liver stiffness measured by transient elastography (FibroScan®) and the efficacy of pegylated interferon alpha-2b plus ribavirin combination treatment for patients with chronic hepatitis C virus (HCV) infection. We prospectively studied 145 Japanese patients with chronic HCV infection. FibroScan was done at baseline, at the end of treatment, and at 48 and 96 weeks after the end of treatment. The FibroScan values were significantly decreased for sustained virological response (SVR) patients (the mean rate of change; -16.2%, -32.2% and -43.5%) in comparison with non-SVR patients (-7.2%, -2.1% and +17.3%) at the end of treatment (P = 0.0127), and 48 weeks (P < 0.0001) and 96 weeks (P < 0.0001) after the end of treatment. Among the non-SVR patients, the FibroScan values were significantly decreased for patients with biochemical response (BR) (-17.9%, -30.0% and -27.1%) in comparison with non-BR (-4.1%, +6.4% and +30.6%) at the end of treatment (P = 0.0270), and 48 weeks (P < 0.0001) and 96 weeks (P < 0.0001) after the end of treatment. The FibroScan values may predict a progressively better clinical outcome for patients with successful virological and biochemical responses.

UR - http://www.scopus.com/inward/record.url?scp=67349145420&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349145420&partnerID=8YFLogxK

U2 - 10.1016/j.antiviral.2009.04.002

DO - 10.1016/j.antiviral.2009.04.002

M3 - Article

VL - 83

SP - 127

EP - 134

JO - Antiviral Research

JF - Antiviral Research

SN - 0166-3542

IS - 2

ER -